Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials | Zendy

Fengping Shao | Zendy; Jun Liu | Zendy; Yaoyun Duan | Zendy; Li Li | Zendy; Liqun Liu | Zendy; Cai Zhang | Zendy; Shanyang He | Zendy

Open Access

Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials

Author(s) -

Fengping Shao,

Jun Liu,

Yaoyun Duan,

Li Li,

Liqun Liu,

Cai Zhang,

Shanyang He

Publication year - 2020

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20192226

Subject(s) - medicine , hazard ratio , placebo , ovarian cancer , poly adp ribose polymerase , oncology , meta analysis , adverse effect , brca mutation , cancer , confidence interval , biology , gastroenterology , polymerase , genetics , pathology , dna , alternative medicine

Poly ADP ribose polymerase (PARP) inhibitors can effectively kill cancer cells by restraining the activity of DNA repair enzymes and utilizing the characteristics of BRCA mutations. This article evaluates the efficacy and safety of PARP inhibitors (PARPis) in the maintenance treatment of ovarian cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research